KR20080112285A - 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 - Google Patents

저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 Download PDF

Info

Publication number
KR20080112285A
KR20080112285A KR1020087024795A KR20087024795A KR20080112285A KR 20080112285 A KR20080112285 A KR 20080112285A KR 1020087024795 A KR1020087024795 A KR 1020087024795A KR 20087024795 A KR20087024795 A KR 20087024795A KR 20080112285 A KR20080112285 A KR 20080112285A
Authority
KR
South Korea
Prior art keywords
diclofenac
dose
compound
pharmaceutical composition
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087024795A
Other languages
English (en)
Korean (ko)
Inventor
커티스 라이트
다니엘 비. 카르
프레드 에이취. 메르멜스타인
Original Assignee
자블린 파머슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38541808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080112285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 자블린 파머슈티칼스 인코포레이티드 filed Critical 자블린 파머슈티칼스 인코포레이티드
Publication of KR20080112285A publication Critical patent/KR20080112285A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020087024795A 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 Ceased KR20080112285A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78648606P 2006-03-28 2006-03-28
US60/786,486 2006-03-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147007290A Division KR20140038575A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형

Publications (1)

Publication Number Publication Date
KR20080112285A true KR20080112285A (ko) 2008-12-24

Family

ID=38541808

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020087024795A Ceased KR20080112285A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020167006852A Ceased KR20160033796A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020177031515A Ceased KR20170123724A (ko) 2006-03-28 2007-03-22 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020157010213A Ceased KR20150050595A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020147007290A Ceased KR20140038575A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167006852A Ceased KR20160033796A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020177031515A Ceased KR20170123724A (ko) 2006-03-28 2007-03-22 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020157010213A Ceased KR20150050595A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR1020147007290A Ceased KR20140038575A (ko) 2006-03-28 2007-03-22 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형

Country Status (12)

Country Link
US (4) US8580954B2 (https=)
EP (3) EP2004203A4 (https=)
JP (3) JP5823093B2 (https=)
KR (5) KR20080112285A (https=)
CN (2) CN101410123A (https=)
AU (1) AU2007230716B2 (https=)
BR (1) BRPI0709409A2 (https=)
CA (1) CA2647348A1 (https=)
IL (2) IL194185A (https=)
MX (1) MX2008012495A (https=)
WO (1) WO2007112272A2 (https=)
ZA (1) ZA200808115B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580954B2 (en) * 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
EP2632553B1 (en) 2010-10-28 2020-01-01 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
MY166036A (en) * 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN107126418B (zh) * 2016-02-25 2020-05-29 江苏思邈医药科技有限公司 供注射用双氯芬酸钠药物组合物及其制备方法
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
US11110073B2 (en) 2017-03-24 2021-09-07 Cadila Healthcare Limited Storage stable aqueous injectable solution comprising diclofenac
GB201720992D0 (en) * 2017-12-15 2018-01-31 Hooper Mark A medical use
WO2021048748A1 (en) 2019-09-09 2021-03-18 Ftf Pharma Private Limited Pharmaceutical formulations comprising diclofenac
US11707443B2 (en) 2019-09-26 2023-07-25 Rk Pharma Inc. Storage stable aqueous parenteral solutions comprising diclofenac
US20240382597A1 (en) * 2021-12-31 2024-11-21 LIVIONEX, Inc. Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984821U (ja) 1982-11-30 1984-06-08 日新電機株式会社 積層コイル
JPS59188644A (ja) 1983-04-09 1984-10-26 Fuji Photo Film Co Ltd 画像形成方法
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
JPS62138437U (https=) 1986-02-26 1987-09-01
YU43290B (en) 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
JPH0616547Y2 (ja) 1986-12-16 1994-05-02 ヒゲタ醤油株式会社 諸味揚槽用濾布
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
JP2575460B2 (ja) * 1988-05-12 1997-01-22 東京田辺製薬株式会社 ダナゾール−シクロデキストリン包接化合物
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
CH679277A5 (https=) 1989-02-09 1992-01-31 Sandoz Ag
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
IT1243342B (it) 1990-07-13 1994-06-10 Farcon Ag Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria
JP3765579B2 (ja) 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
EP1004318A3 (en) 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
DE4207922A1 (de) 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5389681A (en) 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
IT1256386B (it) 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
AU6971294A (en) 1993-06-08 1995-01-03 Novartis Ag Process for the preparation of an oral solid dosage form containing diclofenac
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
GB9316580D0 (en) 1993-08-10 1993-09-29 Smithkline Beecham Plc Pharmaceutical composition
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
GB9318880D0 (en) 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1995013794A1 (en) 1993-11-18 1995-05-26 Nippon Shinyaku Co., Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
ZA949182B (en) 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
JPH10500982A (ja) 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
WO1996011003A1 (en) 1994-10-10 1996-04-18 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
ATE215821T1 (de) 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5821237A (en) 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
AU5774796A (en) 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
TW434023B (en) 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
HUP9600758A2 (en) 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
EP0868915A1 (en) 1997-04-02 1998-10-07 Panacea Biotec Limited An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
EP1049459B1 (en) 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US6365182B1 (en) * 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7186260B2 (en) 1999-04-29 2007-03-06 Hyson Morton I Medicated wrap
US6313370B1 (en) 1999-04-29 2001-11-06 Morton Hyson Medicated wrap
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
WO2000071098A1 (en) 1999-05-24 2000-11-30 Purepac Pharmaceutical Co. A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
ATE283048T1 (de) 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
AU4866001A (en) 2000-03-28 2001-10-08 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CN1729002A (zh) 2000-09-08 2006-02-01 法玛西雅意大利公司 依西美坦作为化学预防剂
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
EP1219306A1 (en) 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
JP2004519490A (ja) 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー エキセメスタンによるホルモン依存性異常症の組合せ治療方法
JP2004525798A (ja) * 2001-03-28 2004-08-26 バイエル アクチェンゲゼルシャフト 情報層中に吸光性化合物としてシアニン色素を含有する光学データ記録媒体
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
FR2830017B1 (fr) 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
EP1443969A2 (en) 2001-10-18 2004-08-11 Decode Genetics EHF Non-inclusion cyclodextrin complexes
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
BR0307518A (pt) 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
EP1476135A1 (en) 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
AU2003241464A1 (en) 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
DE60319221T2 (de) 2002-06-13 2009-03-05 Novartis Ag Quaternisierte ammoniumcyclodextrinverbindungen
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
BR0316673A (pt) 2002-11-27 2005-10-18 Pharmacia Corp Composição lìquida concentrada de valdecoxib
US20060134095A1 (en) 2003-01-27 2006-06-22 Shinobu Ito Antioxidative composition and composition for external use
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
AU2004219595A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050085446A1 (en) 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
TW575271U (en) * 2003-06-25 2004-02-01 Wen-Chin Fan Three-dimensional picture exhibiting device of image display
WO2005042026A1 (ja) 2003-10-31 2005-05-12 Wakamoto Pharmaceutical Co., Ltd. 可逆性熱ゲル化水性組成物
US20050095205A1 (en) 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2005074887A2 (en) 2004-01-30 2005-08-18 Rutgers, The State University Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof
KR20050081092A (ko) 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
US20050203115A1 (en) 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
DK1574221T3 (da) 2004-03-10 2007-07-16 Shimoda Biotech Pty Ltd Stabile, injicérbare diclofenacsammensætninger
DE102004017351A1 (de) * 2004-04-08 2005-10-27 Kalle Gmbh Schlauchförmige Nahrungsmittelhülle mit übertragbarer Innenschicht
EP1761283A2 (en) 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
US20090035315A1 (en) 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases
ITMI20041245A1 (it) 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
TWI279226B (en) 2004-07-20 2007-04-21 Schoeller Textil Ag Dressings which can be applied several times to textile fibres and textile fabrics
GB2417900A (en) 2004-09-11 2006-03-15 Medway Science Technologies Lt Composition for oral drug delivery
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
DE602005027727D1 (de) 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
US7140694B2 (en) * 2005-03-29 2006-11-28 Steven Mason Wheel spoke adjuster guard
KR101255650B1 (ko) * 2005-05-04 2013-04-16 프로노바 바이오파마 너지 에이에스 새로운 ｄｈａ 유도체 및 약제로서의 용도
CN103145839A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CA2613875C (en) 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
RU2008124805A (ru) 2005-11-21 2009-12-27 Шеринг-Плоу Лтд. (CH) Фармацевтические композиции, содержащие бупренорфин
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
US8435965B2 (en) 2005-12-27 2013-05-07 Lion Corporation Composition for soft contact lens and adsorption suppressing method
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
WO2007103435A2 (en) 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
KR20090010953A (ko) 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
US8580954B2 (en) * 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2008006216A1 (en) 2006-07-14 2008-01-17 Mistral Pharma, Inc. Anti-inflammatory and cytoprotectant chronotherapy
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
CN105168186A (zh) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 非粘膜粘着性膜剂型
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
FI20065800A0 (fi) 2006-12-13 2006-12-13 Glykos Finland Oy Polyvalentit biokonjugaatit
EP2120962A1 (en) 2006-12-18 2009-11-25 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
US20100166870A1 (en) 2006-12-21 2010-07-01 The University Of Western Australia Method for Coating Nanoparticles
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
EP1974751A1 (en) 2007-03-26 2008-10-01 The Jordanian Pharmaceutical Manufacturing Co. Formulations for non-steroidal anti-inflammatory drugs
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
WO2008133982A2 (en) 2007-04-27 2008-11-06 Lectec Corporation Adhesive patch with aversive agent
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
MY166036A (en) * 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain

Also Published As

Publication number Publication date
JP5823093B2 (ja) 2015-11-25
JP2016040327A (ja) 2016-03-24
KR20140038575A (ko) 2014-03-28
MX2008012495A (es) 2009-01-07
EP2004203A2 (en) 2008-12-24
EP2522344A1 (en) 2012-11-14
US20150105467A1 (en) 2015-04-16
BRPI0709409A2 (pt) 2011-07-12
KR20170123724A (ko) 2017-11-08
US8580954B2 (en) 2013-11-12
CN101410123A (zh) 2009-04-15
AU2007230716A1 (en) 2007-10-04
CN102846585A (zh) 2013-01-02
IL194185A0 (en) 2009-08-03
KR20150050595A (ko) 2015-05-08
EP2522343A1 (en) 2012-11-14
US20070232566A1 (en) 2007-10-04
KR20160033796A (ko) 2016-03-28
CA2647348A1 (en) 2007-10-04
US20110218247A1 (en) 2011-09-08
EP2004203A4 (en) 2010-03-31
AU2007230716B2 (en) 2012-05-03
JP6157305B2 (ja) 2017-07-05
JP2014005309A (ja) 2014-01-16
JP2009531450A (ja) 2009-09-03
WO2007112272A3 (en) 2007-12-06
JP6265964B2 (ja) 2018-01-24
US20140107209A1 (en) 2014-04-17
US8946292B2 (en) 2015-02-03
IL194185A (en) 2014-11-30
IL222432A (en) 2016-10-31
WO2007112272A2 (en) 2007-10-04
ZA200808115B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
KR20090010953A (ko) 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
KR20080112285A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
EP2635269B1 (en) A combination composition
CN101816643A (zh) 含有双氯芬酸钠和对乙酰氨基酚的药物组合物
EP3233055B1 (en) Injectable formulations of paracetamol
AU2012209035B2 (en) Formulations of low dose diclofenac and beta-cyclodextrin
HK1180247A (en) Formulations of low dose diclofenac and beta-cyclodextrin
JP2005520856A (ja) 貯蔵時に安定なエプレレノン製剤
Qian et al. Effects of intraperitoneal (IP) different doses of ketamine on cognitive function in aged rats: 9AP6-8
HK1150553B (en) Pharmaceutical preparation comprising permethylated cyclodextrin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081010

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130613

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131219

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130613

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140318

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20131219

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101001605

Request date: 20140318

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140319

PJ0201 Trial against decision of rejection

Patent event date: 20140319

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20131219

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101001627

Request date: 20140319

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140319

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140319

Patent event code: PB09011R01I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140318

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20130812

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Appeal kind category: Appeal against decision to decline refusal

Request date: 20140318

Appeal identifier: 2014101001605

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20140319

Effective date: 20160520

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160520

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20140319

Decision date: 20160520

Appeal identifier: 2014101001627